Get started
Work

1466P Napabucasin + nab-paclitaxel with gemcitabine in patients (pts) with metastatic pancreatic adenocarcinoma (mPDAC): Results from the phase III CanStem111P study

Year: 2021
Type: article
DOI: 10.1016/j.annonc.2021.08.794
Authors: T. Bekaii-Saab, T. Okusaka, D. Goldstein, D-Y. Oh, M. Ueno, T. Ioka, W. Fang, E.C. Anderson, M.S. Noel, M. Reni, H.J. Choi, J. Goldberg, S.C. Oh, C-P. Li, J. Tabernero, J. Li, E. Foos, C. Oh, E. Van Cutsem
Institutions: Mayo Clinic in Arizona, National Cancer Center Hospital, Prince of Wales Hospital, Seoul National University, Seoul National University Hospital, Kanagawa Cancer Center, Yamaguchi University, Yamaguchi University Hospital, First Affiliated Hospital Zhejiang University, Zhejiang University, Oregon Health & Science University, OHSU Knight Cancer Institute, Georgetown University Medical Center, MedStar Georgetown University Hospital, IRCCS Ospedale San Raffaele, Yonsei University, Yonsei University Health System, Korea University, Korea University Medical Center, Taipei Veterans General Hospital, Vall d'Hebron Hospital Universitari, Sumitomo Dainippon Pharma (United States), KU Leuven
Language: English
Subfield: Oncology
Field: Medicine
Open Access status: bronze
OpenAlex ID: W3203693572
FWCI: 0.328
Cites:
Cited by: 6
Related to: 10